The most promising cancer treatments for treating cancer will likely get FDA approval soon, and will likely see widespread use by 2025, according to an Axios analysis of cancer drug data.
That means cancer patients with stage III or IV cancer and those with stage IV or lower-stage cancer who have a high-risk disease, such as glioblastoma or breast cancer, could be given the drug, while those with Stage IV or less cancer and for whom the drug does not work will have it on the sidelines.
The analysis also shows that some cancer drugs could have as little as a 10 percent risk of worsening the disease, and a 75 percent chance of improving it.
“If they work well, they are probably going to be approved,” said Andrew Kaczynski, director of the Center for Medicinal Cannabis Research at the University of Florida.
He called the FDA’s plan to approve the most promising treatments “a major step forward.”
“It is likely that they will go to the FDA in 2020,” Kacowski said.
“It has been said that it takes a year for FDA approval.”
The FDA approved a number of drug candidates in the past decade.
But there is an urgent need for them.
“The cancer treatment industry needs more than just the latest therapies.
We need to develop better methods to deliver drugs that deliver the benefits of the cancer,” said J. Michael Bailey, CEO of the American Cancer Society, in a statement.
The agency’s plan is designed to help drugmakers make progress in developing better treatments for the disease.
The FDA is aiming to release its plan next month.
The drugs approved so far include the cancer drugs gliadin and quercetin, and the anti-cancer drug rituximab.
FDA approved five drugs in 2015, including quercolactone, a novel drug that may help treat lung cancer.
The current cancer drugs have a relatively small effect on the cancer cells that cause the disease but have a lower success rate than other types of drugs, according a 2016 review of existing drug trials.
The review also found that there are significant gaps in the research for the drugs and said that there is a risk that new drugs could cause side effects that will be difficult to treat.
“This is not a new situation,” Bailey said.
The new cancer drugs were tested in patients with lung cancer in a clinical trial, and many are being tested in more advanced patients.
“They are not as promising as they were in the early days, but they are promising,” Koczor said.
He added that more research is needed to see how well these drugs help with cancer.
FDA officials declined to comment on whether the agency will try to move faster to approve drugs that can treat advanced cancers.
In its plan, the agency said it will prioritize the most aggressive drugs in each category and make decisions on drugs that would not likely cause side-effects and that were not approved for human use before now.
“We are looking for a pathway to approve as many as 100 drugs for all types of cancer,” FDA Deputy Commissioner David Hickey said in a prepared statement.
“In the meantime, we will continue to support our efforts to find effective and safe new treatments that are as effective as those currently on the market.”
The agency said the FDA is “currently reviewing the clinical trials” for each drug and is also looking into the drug’s potential side effects.
The government is considering the possibility of approving drugs for lung cancer and other cancer types, as well as the potential use of some cancers for the first time.
The Centers for Disease Control and Prevention estimates that about 1.5 million people in the U.S. will have Stage IV cancer by 2025.